EP0266119A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method and formulation for orally administering bioactive agents to and through the Peyer's patch
Assignee: UAB Research Foundation
•
Filing: 1987-10-21
•
Granted: —
•
Expires: 2007-10-21
Abstract
Abstract A method and formulation for orally administering a bioactive agent which comprises encapsulating the agent in one or more biodegradable and biocompatible polymer or copolymer excipients to form a microcapsule which is capable of passing through the gastrointestinal tract unaffected and being taken up by the Peyer's patch.
Inventors
- 👤 Thomas R. Tice
- 👤 Jay K. Staas
- 👤 Richard M. Gilley
- 👤 John H. Eldridge
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-29 21:39
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; C; C07; C07K; C07K16/00; C07K16/44; A61K39/00; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1641; A61K9/1647; A61K9/48; A61K9/50
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
74 words
A method of orally delivering bioactive agent to the Peyer's patch of an animal, comprising the steps of: (a) encapsulating effective amounts of said agent in a biodegradable and biocompatible excipient to form microcapsules of a size capable of passing through the gastrointestinal tract of an animal without degradation or with minimal degradation and being taken up by the Peyer's patch; and (b) orally administering an effective amount of said microcapsules to the animal.
Claim 2
Independent Claim
74 words
A method of orally delivering bioactive agent to the Peyer's patch of an animal, comprising the steps of: (a) encapsulating effective amounts of said agent in a biodegradable and biocompatible excipient to form microcapsules of a size capable of passing through the gastrointestinal tract of an animal without degradation or with minimal degradation and being taken up by the Peyer's patch; and (b) orally administering an effective amount of said microcapsules to the animal.
Claim 3
Dependent Claim
64 words
A composition to be orally administered to animals and capable of delivering a bioactive agent to the Peyer's patch of said animal, comprising an effective amount of a bioactive ingredient encapsulated in a biodegradable and biocompatible excipient so as to form microcapsules of a size capable of being taken up by the Peyer's patch and capable of passing through the gastrointestinal tract without degradation.
Claim 4
Dependent Claim
64 words
A composition to be orally administered to animals and capable of delivering a bioactive agent to the Peyer's patch of said animal, comprising an effective amount of a bioactive ingredient encapsulated in a biodegradable and biocompatible excipient so as to form microcapsules of a size capable of being taken up by the Peyer's patch and capable of passing through the gastrointestinal tract without degradation.
Claim 5
Dependent Claim
18 words
The composition as claimed in Claim 2, wherein said first and second copolymer excipients have different copolymer ratios.
Claim 6
Dependent Claim
17 words
The composition as claimed in Claim 3, wherein said microcapsule is 10 µm or less in diameter.
Claim 7
Dependent Claim
17 words
The composition as claimed in Claim 4, wherein said microcapsule is 5 µm or less in diameter.
Claim 8
Dependent Claim
17 words
The composition as claimed in Claim 4, wherein said microcapsule is 3 µm or less in diameter.
Claim 9
Dependent Claim
13 words
The composition as claimed in Claim 6, wherein said excipient is a polymer.
Claim 10
Dependent Claim
13 words
The composition as claimed in Claim 7, wherein said excipient is a copolymer.
Claim 11
Dependent Claim
33 words
The composition as claimed in Claim 8, wherein said excipient is selected from the group consisting of poly(glycolic acid), copolymers of mixed DL-lactide and glycolide, copolyoxalates, polycaprolactone, poly(lactide-co-caprolactone), poly(esteramides), polyorthoesters and poly(B-hydroxybutyric acid).
Claim 12
Dependent Claim
13 words
The composition as claimed in Claim 9, wherein said copolymer excipient is poly(DL-lactide-co-glycolide).
Claim 13
Dependent Claim
23 words
The composition as claimed in Claim 10, wherein said copolymer excipient has mole rations of lactide to glycolide of 50:50 to 90:10, respectively.
Claim 14
Dependent Claim
21 words
The composition as claimed in Claim 2, wherein at least one said bioactive agent is protozoal, viral, fungal or bacterial antigen.
Claim 15
Dependent Claim
15 words
The composition as claimed in Claim 12, wherein said antigen is trinitrophenyl keyhole limpet hemocyanin.
Claim 16
Dependent Claim
32 words
The composition as claimed in Claim 13, wherein said microcapsules are of diameter from between 1 to 5 µm, said agent is trinitrophenyl keyhole limpet hemocyanin, and said excipient is 50:50 poly(D1-lactide-co-glycolide).
Claim 17
Dependent Claim
14 words
The composition as claimed in Claim 2, wherein said bioactive agent is a toxoid.
Claim 18
Dependent Claim
17 words
The composition as claimed in Claim 15, wherein said toxoid is a toxoid of a staphylococcal enterotoxin.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.